Atsena Reports LIGHTHOUSE data at ARVO - Scorecard - MDSpire

Atsena Reports LIGHTHOUSE data at ARVO

Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The data were presented at the 2025 Association for Research in Vision and Ophthalmology meeting in Salt Lake City, Utah.

  • May 1, 2025

  • 3 min

Share

Clinical Scorecard: Atsena Reports LIGHTHOUSE data at ARVO

At a Glance

CategoryDetail
ConditionX-linked retinoschisis (XLRS)
Key MechanismsGene therapy using ATSN-201 with AAV.SPR capsid for targeted gene expression in photoreceptors.
Target PopulationMale patients ages 6 and older with XLRS caused by RS1 gene mutations.
Care SettingClinical trial setting, specifically a phase 1/2 study.

Key Highlights

  • ATSN-201 shows good safety and efficacy signs in Part A of the LIGHTHOUSE study.
  • No serious adverse events related to treatment reported; most adverse events were Grade 1-2.
  • Enrollment for Part B is ongoing, evaluating additional adult and pediatric patients.

Guideline-Based Recommendations

Diagnosis

  • Clinical diagnosis of XLRS based on RS1 gene mutations.

Management

  • Subretinal injection of ATSN-201 in a dose-escalation and dose-expansion trial.

Monitoring & Follow-up

  • Assessment of safety and efficacy through microperimetry, visual acuity, and macular structure.

Risks

  • Surgical risks related to the procedure; no dose-limiting toxicities observed.

Patient & Prescribing Data

Adult and pediatric patients with XLRS.

ATSN-201 was well tolerated with no treatment-related serious adverse events.

Clinical Best Practices

  • Monitor patients for adverse events related to the surgical procedure.
  • Evaluate preliminary data from adult cohort before dosing pediatric patients.

Related Resources & Content

Original Source(s)

Atsena Reports LIGHTHOUSE data at ARVO

  • May 1, 2025

Related Content

Efficiency in Prior Authorization Practices

Felecia Jones, COT, BBA, Cynthia Matossian, MD, FACS, and Robert F. Melendez, MD, share how ophthalmology practices can make the PA process simpler and more efficient.

Video: No Evidence That AREDS Vitamins Slow GA Progression

A post hoc analysis of OAKS and DERBY data failed to support the foveal protection suggested by an earlier AREDS study.

Evaluation of Laser Doppler Holography for Assessing Choroidal Blood Flow: A Comprehensive Review of Technical Features, Validation Research, and Clinical Uses